About this Research Topic
Breast cancer (BRCA) is the most common cancer affecting women's health worldwide. Radiation therapy (RT) plays a crucial role in the comprehensive management of breast cancer, particularly in cases of early breast cancer after breast-conserving surgery, locally advanced breast cancer, and metastatic breast cancer. However, radioresistance poses a significant challenge to the effectiveness of RT in BRCA treatment. Overcoming radioresistance and enhancing the radiosensitivity of breast cancer to RT have become urgent research priorities.
This Research Topic aims to explore and discuss various aspects related to radioresistance in breast cancer radiotherapy. We will focus on novel radiosensitizing agents, emerging insights into known treatment modalities, and innovative delivery systems. Additionally, we will emphasize the molecular mechanisms underlying breast cancer resistance, as well as the exploration of new biomarkers and therapeutic targets. Original clinical, translational, preclinical research, and review articles focusing on the following areas, but not limited to, are welcome:
1) Exploration of potential biomarkers for predicting breast cancer radiosensitivity.
2) Development of radiogenomics models to predict radiation sensitivity in breast cancer.
3) Analysis of the pathological and molecular characteristics of radioresistant breast cancer.
4) Exploration of novel drugs or approaches to enhance radiosensitivity in breast cancer.
5) Investigation of the underlying molecular mechanisms of radioresistance in breast cancer, aiming to discover new diagnostic and therapeutic targets.
6) Innovations in radiation techniques to overcome radioresistance in breast cancer, such as dose distribution and fractionation patterns.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
This Research Topic aims to explore and discuss various aspects related to radioresistance in breast cancer radiotherapy. We will focus on novel radiosensitizing agents, emerging insights into known treatment modalities, and innovative delivery systems. Additionally, we will emphasize the molecular mechanisms underlying breast cancer resistance, as well as the exploration of new biomarkers and therapeutic targets. Original clinical, translational, preclinical research, and review articles focusing on the following areas, but not limited to, are welcome:
1) Exploration of potential biomarkers for predicting breast cancer radiosensitivity.
2) Development of radiogenomics models to predict radiation sensitivity in breast cancer.
3) Analysis of the pathological and molecular characteristics of radioresistant breast cancer.
4) Exploration of novel drugs or approaches to enhance radiosensitivity in breast cancer.
5) Investigation of the underlying molecular mechanisms of radioresistance in breast cancer, aiming to discover new diagnostic and therapeutic targets.
6) Innovations in radiation techniques to overcome radioresistance in breast cancer, such as dose distribution and fractionation patterns.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: radioresistance, breast cancer, therapeutic modalities, clinical studies, molecular mechanism, radiotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
